Lakefront Biotherapeutics names Dr. Mehdi Shahidi to board
The Euronext- and Nasdaq-listed biotech appointed Shahidi as a non-executive independent director effective November 2, 2026, replacing Paulo Fontoura.
SEC filing
5 stories
The Euronext- and Nasdaq-listed biotech appointed Shahidi as a non-executive independent director effective November 2, 2026, replacing Paulo Fontoura.
SEC filing
A final weekly repurchase of 107,804 shares between October 12 and 16, 2026 completed the June 9, 2026 program, lifting Lakefront's own-share holding to 1,985,157.
SEC filing (11)
Lakefront gets €8 million upfront, up to $230 million in milestones, and royalties as it completes its cell therapy wind-down.
SEC filing